Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by Pandoraon Feb 24, 2021 9:32pm
163 Views
Post# 32654829

RE:RE:news

RE:RE:news
Pandora wrote:
gunzod wrote: Ventripoint issues shares in final payment od Debenture interest.


A little different slant:

 

Ventripoint corrects share issuance from Feb. 10 PR

 

2021-02-24 16:14 ET - News Release

 

An anonymous director reports

CORRECTION -- VENTRIPOINT DIAGNOSTICS ISSUES SHARES IN FINAL PAYMENT OF DEBENTURE INTEREST

Ventripoint Diagnostics Ltd. has made a correction to its Feb. 10, 2021, press release. The Company has issued an aggregate of 96,961 shares, rather than the 131,430 shares previously announced, for the final interest payment of $23,274 on convertible debentures issued by the Company on February 6, 2020, replacement Convertible Debentures issued the same date, and Convertible Debentures issued September 11, 2020. The shares will be issued at a deemed price of $.24 per share. Two directors of the Company will receive a total of 30,186 common shares in final payment of $7,245.88 of interest on their debentures.

All convertible debentures have been converted and the Company is debt free.





If they keep issuing new news releases about this same item I am sure others will get as confused as I am. On February 10 they issue a release re issuing 96,961 shares. They then issued a correction at 16:14 today and now they have issued a third release at 21:05 today about the same 96,961 shares. Good thing they know what they are doing!

 

Ventripoint Diagnostics 96,961 shares for debt

 

2021-02-24 21:05 ET - Shares for Debt

 

This is to confirm that the TSX Venture Exchange has accepted for filing the company's proposal to issue 96,961 common shares to settle outstanding debt for $23,274 of final accrued interest owing on the company's convertible debentures.

Insider:  Robert Hodkginson, 20,123 shares at 24 cents; George Adams, 10,063 shares at 24 cents

For further details, please refer to the company's news release dated Feb. 10, 2021. The company shall issue a news release when the shares are issued and the debt extinguished.

© 2021 Canjex Publishing Ltd. All rights reserved.

<< Previous
Bullboard Posts
Next >>